FDA Memberikan Penunjukan Penyakit Langka Pediatric untuk SAT-3247 untuk Mengobati Distrofi Otot Duchenne

Artikel Terkait

Ryteloᵀᴹ: Terobosan Baru Dalam Pengobatan Myelodysplastic Syndroms Pada Pasien Risiko Rendah

27 Agustus 2024

Duvyzat, Obat Givinostat Oral Telah Disetujui FDA untuk Mengobati Duchenne MD

26 Agustus 2024

FDA Menerima NDA dan Aplikasi Tinjauan Prioritas untuk Vimseltinib pada Tumor Sel Raksasa Tenosinovial

25 Agustus 2024

Referensi

1. Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy. Satellos. News release. August 8, 2024. Accessed August 9, 2024. https://www.businesswire.com/news/home/20240808320005/en/Satellos-Receives-Rare-Pediatric-Disease-Designation-from-the-U.S.-FDA-for-SAT-3247-for-the-Treatment-of-Duchenne-Muscular-Dystrophy

2. Duchenne Muscular Dystrophy. National Library of Medicine. News release. July 10, 2023. Accessed August 9, 2024. https://www.ncbi.nlm.nih.gov/books/NBK482346/#:~:text=Duchenne%20muscular%20dystrophy%20(DMD)%20is%20one%20of%20the%20most%20severe,muscle%20fiber%20degeneration%20and%20weakness.

3. Lambert P. LB: SAT-3247: An Oral Small Molecule Inhibitor Targeting AAK1, a Critical Effector Of Skeletal Muscle Regeneration. MDA Clinical & Scientific Conferece. March 2024. Accessed August 9, 2024. https://www.mdaconference.org/abstract-library/sat-3247-an-oral-small-molecule-inhibitor-targeting-aak1-a-critical-effector-of-skeletal-muscle-regeneration/

4. Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247. Satellos. News release. July 11, 2024. Accessed August 9, 2024. https://ir.satellos.com/news/news-details/2024/Satellos-Announces-Submission-of-Regulatory-Filing-to-Commence-a-Phase-1-Clinical-Trial-with-SAT-3247/default.aspx